Financing fuels Cercle’s expansion into new markets beyond fertility and will bring new LLM capabilities to their AI-driven platform
Cercle, an AI company that unlocks women’s healthcare data at scale into insights for optimal patient and business outcomes, announced it has raised $6 million in seed funding. This financing was led by Outsiders Fund, an early-stage venture capital firm supporting founders who disrupt overlooked, antiquated, and long-standing industries. Additional investments were made by FemHealth Ventures, CGHealth Ventures, and Rogue Women’s Fund. They join existing investors Sheryl Sandberg and Tom Bernthal’s SBVP fund, and a small number of individual angel investors.
Healthcare is inundated with data – but 80% of the data is unstructured and extracting insights from that data is expensive and time consuming. Cercle’s platform, the Cercle Biomedical Graph™, ingests and transforms de-identified healthcare data into real-time, high-quality insights that women’s healthcare providers use to run more efficient businesses and provide more personalized care. It does so at an unprecedented speed and scale without AI hallucinations.
Cercle will use this seed funding to widen its application beyond the fertility market, expand its global footprint, and fuel its engineering and product development efforts, including advancement of the company’s LLM offerings. Co-Founder and CEO Juan Carlos Riveiro leads the company and all technical efforts. As an experienced technologist and entrepreneur in AI and machine learning, he is driving the engineering work to connect LLMs to high quality women’s healthcare data. This AI advancement will result in secure, accurate and real-time answers to questions asked by women’s healthcare stakeholders. Cercle aims to broaden its customer base across the women’s healthcare ecosystem, reaching providers, payers, and pharma who work on reproductive health, menopause, women’s oncology, and other rare diseases that disproportionately impact women.
“Women’s healthcare is under researched, underfunded, and underserved,” said Ashley Finch, Cercle’s COO. “Our mission at Cercle is simple and clear: to leverage the power of AI to generate insights from women’s health data in order to drive efficiencies for providers, develop drugs faster, and improve care for patients. We are thrilled that this group of investors, led by Outsiders Fund, shares our passion for women’s healthcare and understands that transforming data into insights is a critical step to improve both business and clinical outcomes in women’s healthcare.”
Also Read: Zynx Health & Innovaccer Boost Population Health Management
Since its introduction in November 2023, the Cercle Biomedical Graph has been used by US Fertility, Boston IVF, and Eurofins Genoma, Cercle’s European-based distributor, among others, to drive efficiency for clinics and inform personalized treatments for fertility patients. These early partnerships have resulted in a thorough and wide-ranging knowledge base of women’s health data that have improved the efficiency and efficacy of medical care–from providing more accurate, realistic timelines and procedural options to setting reasonable, scientifically validated expectations with the patient.
“Cercle is a truly exciting innovator at the intersection of AI and women’s healthcare,” said George Easley, Principal at Outsiders Fund. “Cercle’s leadership team possesses a rare set of technical and operational skills that uniquely positions them to reimagine the uses of AI in and the data infrastructure of women’s healthcare. The company’s best-in-class infrastructure, LLM interface, and ML / AI models provide serious leverage to clinicians and healthcare operators alike. We are proud to lead this seed round and excited about what the future holds for Cercle.”
“Cercle’s unique AI platform has meaningfully enhanced both our business operations and clinical workflows,” stated Dr. Eduardo Hariton, VP of Strategic Initiatives at US Fertility and Managing Director of the Innovation Fund. “Analyzing raw data for actionable insights is labor-intensive and costly. Cercle’s AI platform enables us to extract these insights more efficiently and at scale, leading to both better outcomes for our business and a better experience for our patients.”
The Cercle Biomedical Graph is HIPAA and GDPR compliant, ensuring the highest degrees of data privacy and security. Acting as a mediary between patient data records and LLMs, the Cercle Biomedical Graph removes all personal information and anonymizes data points and insights. To date, it has captured and analyzed more than one billion data points from anonymized patients globally. The Cercle Biomedical Graph has not been evaluated by the U.S. Food and Drug Administration. It does not diagnose, treat, cure, or prevent any disease and is not classified as a medical device.
Source: Businesswire
